+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sickle Cell Disease Treatment Market - Global Forecast 2026-2032- Product Image
Sickle Cell Disease Treatment Market - Global Forecast 2026-2032- Product Image
New

Sickle Cell Disease Treatment Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 188 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6024723
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The sickle cell disease treatment market is advancing rapidly, influenced by new therapies, evolving care delivery, and a central emphasis on access and equity. Senior decision-makers must act on strategic intelligence that spans clinical innovation, supply chain optimization, and shifting reimbursement trends.

Market Snapshot: Sickle Cell Disease Treatment Market

The Sickle Cell Disease Treatment Market is projected to expand from USD 1.99 billion in 2025 to USD 2.10 billion in 2026, attaining a CAGR of 6.75% and reaching USD 3.14 billion by 2032. This growth is fueled by the adoption of advanced therapies, evolving payer frameworks, and increased disease awareness. Market developments reflect heightened demand for disease-modifying agents and underscore the necessity for robust and adaptable supply chains. Regions at different stages of readiness for innovative treatments contribute to diverse market adoption patterns and operational realities.

Scope & Segmentation

  • Drug Classes: Analgesics are critical for managing acute pain, while disease-modifying agents such as hydroxyurea and infection-preventing antibiotics support ongoing care. Newer options include gene therapies and bone marrow transplants, offering curative potential for certain patient subsets.
  • Therapy Types: Established approaches like blood transfusions and hydroxyurea continue to play a key role, complemented by the introduction of gene correction, gene addition therapies, and transplants for select populations.
  • Distribution Channels: Hospital pharmacies drive acute and advanced intervention management; retail and online pharmacies are expanding their presence in the landscape of chronic therapy and patient adherence strategies.
  • End-User Settings: Hospitals, ambulatory care centers, and specialized clinics remain central to treatment provision. Community-based programs are increasingly pivotal for guiding patients through long-term care pathways.
  • Regions: The market includes the Americas, Europe, Middle East, Africa, and Asia-Pacific. Each region demonstrates varying levels of readiness and infrastructure to support advanced therapies and diagnostics, affecting both speed and scale of adoption.
  • Technologies: Advances in gene therapy, new conditioning regimens, apheresis techniques, and specialized cold-chain logistics are vital for safe and effective therapy delivery, especially for highly specialized or cellular treatments.

Key Takeaways

  • Therapeutic innovation is shifting the treatment landscape toward early disease modification and improved patient outcomes over time, rather than focusing only on acute crisis management.
  • Stakeholders now expect clear evidentiary endpoints and robust safety measures outside of controlled clinical settings, demanding operational consistency.
  • Integrated care pathways, blending pharmacologic advances with specialty center infrastructure and effective patient engagement, are shaping adoption rates and influencing competitive positioning across the sector.
  • Ensuring equitable access relies on community-centric education, comprehensive support services, and persistent attention to historic care disparities.
  • Commercial success increasingly depends on differentiating from competitors in payer strategies, considering total cost of care, and optimizing therapy transition protocols for efficiency.
  • Maintaining company reputation and visible long-term commitment to patient communities is critical for building ongoing trust and promoting therapy uptake in varied populations.

Tariff Impact & Supply Chain Considerations

Recent US tariffs impose added operational complexity for manufacturers, including for biologics, cell-processing consumables, and lab supplies. These changes intensify cost variability and influence both procurement and availability, particularly for therapies relying on international supply networks. Mitigating strategies such as supplier diversification, dual sourcing, and targeted local sourcing of core components help reduce risks and maintain quality standards. Input cost changes may also prompt closer payer examination, reinforcing the need for compelling value demonstration and clear alignment between trade policy and therapy adoption trends.

Methodology & Data Sources

This research is built on a thorough, multi-layered approach. Structured secondary review of therapeutic classes, clinical guidance, and regulatory updates is paired with primary validation via expert interviews. Triangulation of stakeholder feedback identifies repeated barriers and operational patterns, grounding insights in practical realities and aligning recommendations with executive decision-making needs.

Why This Report Matters

  • Guides strategic planning by mapping how scientific innovation, payer strategies, and operational readiness intersect within the sickle cell disease treatment market.
  • Equips decision-makers with segmentation insights and the latest tariff impact analysis, crucial for supply continuity and maintaining competitive positioning.
  • Enables the development of frameworks grounded in patient equity and validated evidence, supporting better outcomes and effective resource use.

Conclusion

Combining innovation, supply chain strength, and equity-focused care delivery is fundamental for long-term competitiveness. Leaders who align evidence, operational adaptability, and lasting community engagement will achieve sustainable success in this complex market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Sickle Cell Disease Treatment Market, by Treatment Type
8.1. Blood Transfusion
8.1.1. Acute Transfusion
8.1.2. Chronic Transfusion
8.2. Bone Marrow Transplant
8.2.1. Allogeneic Transplant
8.2.2. Autologous Transplant
8.3. Pharmacotherapy
8.3.1. Endari (L-Glutamine) Treatment
8.3.2. Gene Therapy
8.3.3. Hydroxyurea Treatment
9. Sickle Cell Disease Treatment Market, by Patient Age Group
9.1. Adult
9.2. Pediatric
10. Sickle Cell Disease Treatment Market, by Drug Administration Method
10.1. Intravenous
10.2. Oral
11. Sickle Cell Disease Treatment Market, by Disease Type
11.1. Hemoglobin SC Disease (HbSC)
11.2. Sickle Cell Anemia (HbSS)
12. Sickle Cell Disease Treatment Market, by End User
12.1. Clinics
12.2. Hospitals
12.2.1. Private Hospitals
12.2.2. Public Hospitals
12.3. Research Institutions
13. Sickle Cell Disease Treatment Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Sickle Cell Disease Treatment Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Sickle Cell Disease Treatment Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Sickle Cell Disease Treatment Market
17. China Sickle Cell Disease Treatment Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Akums Drugs and Pharmaceuticals Ltd.
18.6. Beam Therapeutics, Inc.
18.7. Biogen Inc.
18.8. Bluebird Bio, Inc.
18.9. Bristol-Myers Squibb Company
18.10. CRISPR Therapeutics AG
18.11. Editas Medicine, Inc.
18.12. Emmaus Medical, Inc.
18.13. F. Hoffmann-La Roche AG
18.14. GlycoMimetics, Inc.
18.15. Intellia Therapeutics, Inc.
18.16. Medunik USA
18.17. Novartis AG
18.18. Protagonist Therapeutics, Inc.
18.19. Sangamo Therapeutics, Inc.
18.20. Sanofi S.A.
18.21. Vertex Pharmaceuticals, Inc.
18.22. Vor Biopharma, Inc.
List of Figures
FIGURE 1. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ACUTE TRANSFUSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ACUTE TRANSFUSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ACUTE TRANSFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY CHRONIC TRANSFUSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY CHRONIC TRANSFUSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY CHRONIC TRANSFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ALLOGENEIC TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ALLOGENEIC TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ALLOGENEIC TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY AUTOLOGOUS TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY AUTOLOGOUS TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY AUTOLOGOUS TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ENDARI (L-GLUTAMINE) TREATMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ENDARI (L-GLUTAMINE) TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ENDARI (L-GLUTAMINE) TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HYDROXYUREA TREATMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HYDROXYUREA TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HYDROXYUREA TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HEMOGLOBIN SC DISEASE (HBSC), BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HEMOGLOBIN SC DISEASE (HBSC), BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HEMOGLOBIN SC DISEASE (HBSC), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY SICKLE CELL ANEMIA (HBSS), BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY SICKLE CELL ANEMIA (HBSS), BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY SICKLE CELL ANEMIA (HBSS), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 77. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
TABLE 82. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 83. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 84. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
TABLE 92. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 93. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 97. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 99. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 100. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 101. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
TABLE 102. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 103. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 104. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 115. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 117. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
TABLE 118. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 119. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 120. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 121. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
TABLE 122. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 123. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 124. EUROPE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 125. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 127. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
TABLE 128. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 129. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 130. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 131. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
TABLE 132. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 133. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 135. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 136. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 137. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
TABLE 138. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 139. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 140. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 141. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
TABLE 142. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 143. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 144. AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 155. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 156. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 157. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 158. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
TABLE 159. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 160. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 161. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 162. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
TABLE 163. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 164. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 165. ASEAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 166. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 167. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 168. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
TABLE 169. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 170. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 171. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 172. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
TABLE 173. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 174. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 175. GCC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 176. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 177. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 178. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 186. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 188. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
TABLE 189. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 190. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 191. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 192. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
TABLE 193. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 194. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 195. BRICS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 196. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 197. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 198. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
TABLE 199. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 200. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 201. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 202. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
TABLE 203. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 204. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 205. G7 SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 206. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 207. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 208. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
TABLE 209. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 210. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 211. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 212. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
TABLE 213. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 214. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 215. NATO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 216. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 217. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 218. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 219. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
TABLE 220. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 221. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 222. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 223. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
TABLE 224. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 225. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 226. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 227. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 228. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 229. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2032 (USD MILLION)
TABLE 230. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2032 (USD MILLION)
TABLE 231. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 232. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 233. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2032 (USD MILLION)
TABLE 234. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 235. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 236. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Sickle Cell Disease Treatment market report include:
  • Akums Drugs and Pharmaceuticals Ltd.
  • Beam Therapeutics, Inc.
  • Biogen Inc.
  • Bluebird Bio, Inc.
  • Bristol-Myers Squibb Company
  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • Emmaus Medical, Inc.
  • F. Hoffmann-La Roche AG
  • GlycoMimetics, Inc.
  • Intellia Therapeutics, Inc.
  • Medunik USA
  • Novartis AG
  • Protagonist Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi S.A.
  • Vertex Pharmaceuticals, Inc.
  • Vor Biopharma, Inc.

Table Information

Report AttributeDetails
No. of Pages188
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.1 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.14 Billion
Compound Annual Growth Rate6.7%
Regions CoveredGlobal
No. of Companies Mentioned19

Related Topics

Related Reports

Sickle Cell Disease Treatment Market Report 2025 - Product Image

Sickle Cell Disease Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Sickle Cell Anemia Therapeutic Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Sickle Cell Anemia Therapeutic Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Sickle Cell Disease Treatment Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034) - Product Image

Sickle Cell Disease Treatment Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034)

  • Report
  • 400 Pages
  • Global
From
Sickle Cell Disease Treatment - Global Strategic Business Report - Product Image

Sickle Cell Disease Treatment - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
Sickle Cell Disease (SCD) - Market Insight, Epidemiology, and Market Forecast - 2034 - Product Image

Sickle Cell Disease (SCD) - Market Insight, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.